X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home News

US Study Finds COVID Raises Long-Term Brain Injury Risk

Content Team by Content Team
24th September 2022
in News, Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

According to a study published on September 22nd by U.S. researchers, those who had COVID-19 were more likely to experience a variety of brain damage a year later than those who had never had the coronavirus. This result may have implications for millions of Americans.

The one-year study, which was reported in Nature Medicine, used anonymized medical records from millions of U.S. veterans to evaluate brain health across 44 distinct illnesses. Compared to a similar sample of veterans who had never been infected with COVID, 7% more of those with COVID had brain and other neurological abnormalities. According to the team, this amounts to around 6.6 million Americans who experienced brain damage as a result of their COVID infections.

According to senior author Dr. Ziyad Al-Aly of the Washington University School of Medicine, the results reveal the terrible long-term effects of COVID-19.

Al-Aly and colleagues at the Veterans Affairs St. Louis Health Care System and Washington University School of Medicine examined the medical files of 154,000 American veterans who had tested positive for COVID between March 1, 2020, and January 15, 2021.

These were contrasted with data from 5.6 million individuals who were COVID-free during the same time period and a separate sample of 5.8 million people during the time just before the coronavirus entered the United States. Prior research, according to Al-Aly, focused mostly on patients who were hospitalised and looked at a smaller number of illnesses, but his study covered both hospitalised and out-of-hospital patients.

The most prevalent symptom was memory loss, sometimes known as brain fog. People with COVID showed a 77% higher probability of having memory issues compared to the control groups.

Those who had the virus were also 50% more likely than those who had never had it to get an ischemic stroke, which is brought on by blood clots.

In comparison to the control groups, those with COVID were 82% more likely to experience seizures, 43% more likely to experience mental health conditions like worry or despair, 35% more likely to experience headaches, and 42% more likely to experience movement disorders like tremors.

Governments and healthcare systems must create plans for a post-COVID era, according to researchers. Given the enormous magnitude of the pandemic, Al-Aly stated that urgent and coordinated global, national, and regional response measures are needed in order to face these difficulties.

Previous Post

Herpes By Being Genetically Altered Fights Severe Cancers

Next Post

Amyotrophic Lateral Sclerosis- FDA And NIH Learning More

Related Posts

idiopathic pulmonary fibrosis
Americas

US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

9th October 2025
Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
FastTrack Review
Americas

US FDA Launches Fast-Track Review Scheme for Generic Drugs

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
API Manufacturing Facility
Americas

AbbVie Launches New API Manufacturing Facility in Illinois

1st October 2025
U.S. manufacturing
Americas

Amgen to Expand U.S. Manufacturing with $650M Investment

30th September 2025
Next Post

Amyotrophic Lateral Sclerosis- FDA And NIH Learning More

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In